Brett Alldredge, DO
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $26,850 of the $37,109 with a category attached, or 72.4%. Genentech USA, Inc. accounts for 98.6% of it on its own, with 5 other manufacturers making up the rest.
Across 52 payments — averaging $713.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$37K
- Biogen$300
- Novartis$110
- SK Life Science, Inc.$57
- TG Therapeutics, Inc.$37
- UCB, Inc.$15
What the payments were for
- Consulting fees$5,69015%
- Speaking & faculty fees$26,85072%
- Travel & lodging$3,58210%
- Food & beverage$9723%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 41 | $36,589 |
| Biogen | 2 | $300 |
| Novartis | 6 | $110 |
| SK Life Science, Inc. | 1 | $57 |
| TG Therapeutics, Inc. | 1 | $37 |
| UCB, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OCREVUS$35,998
- Ocrevus Zunovo$13,956
- TYSABRI$300
How this compares
$37,109 in reported general payments places this provider in the 85th percentile of 157 neurology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CopaxoneGlatiramer Acetate | 26 | $154,663 |
| GlatopaGlatiramer Acetate | 22 | $38,756 |
| Aimovig AutoinjectorErenumab-Aooe | 37 | $27,754 |
| Emgality SyringeGalcanezumab-Gnlm | 13 | $22,372 |
| UbrelvyUbrogepant | 19 | $18,113 |
| Ajovy SyringeFremanezumab-Vfrm | 25 | $17,919 |
| Dalfampridine ErDalfampridine | 40 | $17,620 |
| Nurtec OdtRimegepant Sulfate | 16 | $16,543 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 148 | $8,770 |
| Mycophenolate Mofetil | 57 | $8,593 |
| Emgality PenGalcanezumab-Gnlm | 12 | $8,211 |
| Levetiracetam | 176 | $7,740 |
| Tetrabenazine | 14 | $7,479 |
| Lamotrigine ErLamotrigine | 21 | $5,658 |
| Lacosamide | 36 | $3,907 |
Paid to pharmacies, not to this prescriber.
Other neurology in Ogden
- Richard HammondOgden$707K
- Trevor SquireOgden$112K
- Timothy WestSalt Lake City$856K
- Jeffrey GrovesDraper$628K
- Stacey SteevesSalt Lake City$548K
- Amir ArainSalt Lake City$329K
- Mark BrombergSalt Lake City$265K
- April ErwinSalt Lake City$263K
- Yashma PatelLehi$251K
- Albert SmithSalt Lake City$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.